Item request has been placed!

Item request cannot be made.

Processing Request

Search Results

Display Settings

Results per page: 10

Sort By: Relevance

Your Filters

Subject : myelodysplastic syndromes

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Authors : Navas T; Scios Inc, Fremont, CA, USA.; Zhou L

Subjects: Bone Marrow/Bone Marrow/Bone Marrow/*pathology ; Inflammation Mediators/Inflammation Mediators/Inflammation Mediators/*antagonists & inhibitors ; Myelodysplastic Syndromes/Myelodysplastic Syndromes/Myelodysplastic Syndromes/*pathology

Source: Leukemia & lymphoma [Leuk Lymphoma] 2008 Oct; Vol. 49 (10), pp. 1963-75.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print Cited Medium: Internet ISSN: 1029-2403

Read Online Read More Add to Saved list

Academic Journal

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.

Authors : Sokol, L¹; Cripe, L²; Kantarjian, H³

Source: Leukemia (08876924). Apr2013, Vol. 27 Issue 4, p977-980. 4p. 2 Charts.

Read Online Read More Add to Saved list

Report

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Source: A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic

Read More Add to Saved list